- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05882058
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
DAREON™-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas
This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists.
The purpose of this study is to find a suitable dose of BI 764532 that people with advanced cancer can tolerate when taken alone. 2 different doses of BI 764532 are tested in this study. Another purpose is to check whether BI 764532 can make tumours shrink. BI 764532 is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer.
Participants are put into 2 groups randomly, which means by chance. One group gets dose 1 of BI 764532 and the other group gets dose 2 of BI 764532. Participants get BI 764532 infusions into a vein when starting treatment. If there is benefit for the participants and if they can tolerate it, the treatment is given up to the maximum duration of the study. During this time, participants visit the study site regularly. The total number of visits depends on how they respond to and tolerate the treatment. The first study visits include an over-night stay to monitor participants' safety. Doctors record any unwanted effects and regularly check the general health of the participants.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Boehringer Ingelheim
- Phone Number: 1-800-243-0127
- Email: clintriage.rdg@boehringer-ingelheim.com
Study Locations
-
-
-
Gent, Belgium, 9000
- Recruiting
- UNIV UZ Gent
-
Contact:
- Boehringer Ingelheim
- Phone Number: 080049616
- Email: belgique@bitrialsupport.com
-
Leuven, Belgium, 3000
- Recruiting
- UZ Leuven
-
Contact:
- Boehringer Ingelheim
- Phone Number: 080049616
- Email: belgique@bitrialsupport.com
-
-
-
-
-
Panagyurishte, Bulgaria, 4500
- Recruiting
- MHAT UniHospital
-
Contact:
- Boehringer Ingelheim
- Phone Number: 024903378
- Email: balgariya@bitrialsupport.com
-
Pleven, Bulgaria, 5800
- Recruiting
- MHAT Heart and Brain
-
Contact:
- Boehringer Ingelheim
- Phone Number: 024903378
- Email: balgariya@bitrialsupport.com
-
-
-
-
-
Chengdu, China, 610041
- Recruiting
- West China Hospital
-
Contact:
- Boehringer Ingelheim
- Phone Number: 4001200553
- Email: china@bitrialsupport.com
-
Hangzhou, China, 310016
- Recruiting
- Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
-
Contact:
- Boehringer Ingelheim
- Phone Number: 4001200553
- Email: china@bitrialsupport.com
-
Jinan, China, 250031
- Recruiting
- 960 Hospital of the Chinese People's Liberation Army
-
Contact:
- Boehringer Ingelheim
- Phone Number: 4001200553
- Email: china@bitrialsupport.com
-
Jinan, China, 250012
- Recruiting
- Qilu Hospital, Shangdong University
-
Contact:
- Boehringer Ingelheim
- Phone Number: 4001200553
- Email: china@bitrialsupport.com
-
Nanchang, China, 330006
- Recruiting
- The Second Affiliated Hospital to Nanchang University
-
Contact:
- Boehringer Ingelheim
- Phone Number: 4001200553
- Email: china@bitrialsupport.com
-
Shanghai, China, 200030
- Recruiting
- Shanghai Chest Hospital
-
Contact:
- Boehringer Ingelheim
- Phone Number: 4001200553
- Email: china@bitrialsupport.com
-
-
-
-
-
Berlin, Germany, 13125
- Recruiting
- Evangelische Lungenklinik Berlin
-
Contact:
- Boehringer Ingelheim
- Phone Number: 08007234742
- Email: deutschland@bitrialsupport.com
-
Dresden, Germany, 01307
- Recruiting
- Universitätsklinikum Carl Gustav Carus Dresden
-
Contact:
- Boehringer Ingelheim
- Phone Number: 08007234742
- Email: deutschland@bitrialsupport.com
-
Erlangen, Germany, 91054
- Recruiting
- Universitätsklinikum Erlangen
-
Contact:
- Boehringer Ingelheim
- Phone Number: 08007234742
- Email: deutschland@bitrialsupport.com
-
Gauting, Germany, 82131
- Recruiting
- Asklepios Fachkliniken München-Gauting
-
Contact:
- Boehringer Ingelheim
- Phone Number: 08007234742
- Email: deutschland@bitrialsupport.com
-
Großhansdorf, Germany, 22927
- Recruiting
- LungenClinic Grosshansdorf GmbH
-
Contact:
- Boehringer Ingelheim
- Phone Number: 08007234742
- Email: deutschland@bitrialsupport.com
-
Mainz, Germany, 55131
- Recruiting
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz
-
Contact:
- Boehringer Ingelheim
- Phone Number: 08007234742
- Email: deutschland@bitrialsupport.com
-
-
-
-
-
Aichi, Nagoya, Japan, 464-8681
- Recruiting
- Aichi Cancer Center Hospital
-
Contact:
- Boehringer Ingelheim
- Phone Number: 0120201230
- Email: nippon@bitrialsupport.com
-
Chiba, Kashiwa, Japan, 277-8577
- Recruiting
- National Cancer Center Hospital East
-
Contact:
- Boehringer Ingelheim
- Phone Number: 0120201230
- Email: nippon@bitrialsupport.com
-
Miyagi, Sendai, Japan, 980-0873
- Recruiting
- Sendai Kousei Hospital
-
Contact:
- Boehringer Ingelheim
- Phone Number: 0120201230
- Email: nippon@bitrialsupport.com
-
Osaka, Osaka, Japan, 541-8567
- Recruiting
- Osaka International Cancer Institute
-
Contact:
- Boehringer Ingelheim
- Phone Number: 0120201230
- Email: nippon@bitrialsupport.com
-
Osaka, OsakaSayama, Japan, 589-8511
- Recruiting
- Kindai University Hospital
-
Contact:
- Boehringer Ingelheim
- Phone Number: 0120201230
- Email: nippon@bitrialsupport.com
-
Tokyo, Chuo-ku, Japan, 104-0045
- Recruiting
- National Cancer Center Hospital
-
Contact:
- Boehringer Ingelheim
- Phone Number: 0120201230
- Email: nippon@bitrialsupport.com
-
Tokyo, Koto-ku, Japan, 135-8550
- Recruiting
- Japanese Foundation for Cancer Research
-
Contact:
- Boehringer Ingelheim
- Phone Number: 0120201230
- Email: nippon@bitrialsupport.com
-
-
-
-
-
Seoul, Korea, Republic of, 05505
- Recruiting
- Asan Medical Center
-
Contact:
- Boehringer Ingelheim
- Phone Number: 0808802084
- Email: namhan@bitrialsupport.com
-
Seoul, Korea, Republic of, 06351
- Recruiting
- Samsung Medical Center
-
Contact:
- Boehringer Ingelheim
- Phone Number: 0808802084
- Email: namhan@bitrialsupport.com
-
Seoul, Korea, Republic of, 03722
- Recruiting
- Severance Hospital
-
Contact:
- Boehringer Ingelheim
- Phone Number: 0808802084
- Email: namhan@bitrialsupport.com
-
-
-
-
-
Lisboa, Portugal, 1350-352
- Recruiting
- Hospital CUF Tejo
-
Contact:
- Boehringer Ingelheim
- Phone Number: 800856070
- Email: portugal@bitrialsupport.com
-
Porto, Portugal, 4100-180
- Recruiting
- Hospital CUF Porto
-
Contact:
- Boehringer Ingelheim
- Phone Number: 800856070
- Email: portugal@bitrialsupport.com
-
-
-
-
-
Barcelona, Spain, 08003
- Recruiting
- Hospital del Mar
-
Contact:
- Boehringer Ingelheim
- Phone Number: 900876092
- Email: espana@bitrialsupport.com
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Vall d'Hebron
-
Contact:
- Boehringer Ingelheim
- Phone Number: 900876092
- Email: espana@bitrialsupport.com
-
Madrid, Spain, 28041
- Recruiting
- Hospital Universitario 12 de Octubre
-
Contact:
- Boehringer Ingelheim
- Phone Number: 900876092
- Email: espana@bitrialsupport.com
-
Malaga, Spain, 29010
- Recruiting
- Hospital Virgen de la Victoria
-
Contact:
- Boehringer Ingelheim
- Phone Number: 900876092
- Email: espana@bitrialsupport.com
-
Valencia, Spain, 46010
- Recruiting
- Hospital Clinico de Valencia
-
Contact:
- Boehringer Ingelheim
- Phone Number: 900876092
- Email: espana@bitrialsupport.com
-
-
-
-
-
Tainan, Taiwan, 704
- Recruiting
- NCKUH
-
Contact:
- Boehringer Ingelheim
- Phone Number: 0809092098
- Email: taiwan@bitrialsupport.com
-
Taipei, Taiwan, 11217
- Recruiting
- Taipei Veterans General Hospital
-
Contact:
- Boehringer Ingelheim
- Phone Number: 0809092098
- Email: taiwan@bitrialsupport.com
-
Taoyuan County, Taiwan, 333
- Recruiting
- Chang Gung Memorial Hospital(Linkou)
-
Contact:
- Boehringer Ingelheim
- Phone Number: 0809092098
- Email: taiwan@bitrialsupport.com
-
-
-
-
-
Leicester, United Kingdom, LE1 5WW
- Recruiting
- Leicester Royal Infirmary
-
Contact:
- Boehringer Ingelheim
- Phone Number: 08000514022
- Email: unitedkingdom@bitrialsupport.com
-
London, United Kingdom, WC1E 6AG
- Recruiting
- University College Hospital
-
Contact:
- Boehringer Ingelheim
- Phone Number: 08000514022
- Email: unitedkingdom@bitrialsupport.com
-
Newcastle Upon Tyne, United Kingdom, NE7 7DN
- Recruiting
- Freeman Hospital
-
Contact:
- Boehringer Ingelheim
- Phone Number: 08000514022
- Email: unitedkingdom@bitrialsupport.com
-
-
-
-
Alabama
-
Mobile, Alabama, United States, 36607
- Recruiting
- Infirmary Cancer Care
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
-
California
-
Los Angeles, California, United States, 90067
- Recruiting
- Valkyrie Clinical Trials
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
San Francisco, California, United States, 94143
- Recruiting
- University of California San Francisco
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- University of Miami
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Indiana University
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- Recruiting
- University of Kentucky Medical Center
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Dana-Farber Cancer Institute
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
-
New York
-
Bronx, New York, United States, 10461
- Recruiting
- Montefiore Medical Center
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
New York, New York, United States, 10016
- Recruiting
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Male or female participants ≥18 years old and at least at the legal age of consent in countries where it is greater than 18 years at the time of signature of the informed consent form (ICF).
- Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
Histologically or cytologically confirmed, cancer of the following histologies:
- Small cell lung cancer (SCLC)
- Extra-pulmonary neuroendocrine carcinoma (epNEC) (except Merkel cell carcinoma (MCC), Medullary thyroid cancer (MTC) and Neuroendocrine prostate cancer (NEPC))
- Large cell neuroendocrine carcinoma (LCNEC) of the lung Patients with tumours with mixed histologies for any above type are eligible only if the neuroendocrine carcinoma/small tumour cells component is predominant and represents at least 50% of the overall tumour tissue.
Patients must have progressed or recurred after standard of care therapy
- SCLC: after at least two prior lines of therapy, including at least one platinum-based regimen; in countries where standard of care in first line therapy includes PD-L1 inhibitor treatment patients should have received the combination of platinum-based regimen plus PD-L1 inhibitor unless they have been unable to receive checkpoint inhibitor treatment.
- epNEC/LCNEC: after at least one platinum-based regimen
- Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
- Measurable lesions as defined per Response Evaluation Criteria In Solid Tumours (RECIST) v 1.1 within 21 days prior to the first dose of BI 764532.
- Availability of archival tumour tissue sample.
- Adequate organ function as defined in the protocol.
- All toxicities related to previous anti-cancer therapies have resolved = Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 prior to trial treatment administration (except for alopecia, peripheral neuropathy, fatigue and endocrinopathies controlled by replacement therapy which must be = CTCAE Grade 2 and amenorrhea/menstrual disorders which can be any grade).
- Women of childbearing potential (WOCBP)and men able to father a child must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of their use is provided in the participant information
Exclusion criteria:
Untreated or symptomatic brain metastases. Participants with treated, stable brain metastases are eligible provided they meet the following criteria:
- Radiotherapy or surgery for brain metastases was completed at least 2 weeks prior to the first administration of BI 764532.
- Patient is off steroids for at least 7 days (physiologic doses of steroids are permitted), and the patient is off anti-epileptic drugs for at least 7 days or on stable doses of anti-epileptic drugs for malignant central nervous system (CNS) disease.
- Presence of leptomeningeal disease.
- Active/previous history of interstitial lung disease or non-infectious pneumonitis (any grade).
- Participants who experienced severe, life-threatening immune-mediated adverse events or infusion-related reactions including those that lead to permanent discontinuation while on treatment with immuno-oncology agents.
Prior anti-cancer therapy:
- Patients who have been treated with any other anti-cancer drug within 4 weeks or within 5 half-life periods (whichever is shorter) prior to first administration of BI 764532.
- Patients who have been treated with extensive field radiotherapy including whole brain irradiation within 2 weeks prior to first administration of BI 764532.
- Previous treatment with Delta-like ligand 3 (DLL3)-targeting T cell engagers or cell therapies.
- Diagnosis of immunodeficiency or systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of BI 764532. Physiological replacement of steroids is allowed.
- Unresolved toxicity from prior anti-tumour therapy, defined as per protocol. Further exclusion criteria apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose group 1
|
BI 764532, formulation 1
BI 764532, formulation 2
|
Experimental: Dose group 2
|
BI 764532, formulation 1
BI 764532, formulation 2
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response (OR), defined as a best overall response of confirmed complete response (CR) or confirmed partial response (PR)
Time Frame: up to 23 months
|
according to RECIST v 1.1 by investigator assessment from the date of treatment start until the earliest date of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent.
|
up to 23 months
|
Occurrence of treatment-emergent adverse events (TEAEs) during the on-treatment period
Time Frame: up to 23 months
|
up to 23 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of objective response (DOR) based on investigator assessment
Time Frame: up to 23 months
|
DOR is defined as the time from first documented confirmed OR until the earliest date of disease progression or death among patients with confirmed OR.
|
up to 23 months
|
Progression-free survival (PFS) based on investigator assessment
Time Frame: up to 23 months
|
PFS is defined as the time from treatment start until the earliest date of tumour progression according RECIST v 1.1 or death from any cause, whichever occurs first.
|
up to 23 months
|
Disease control (DC), defined as best overall response of CR or PR or stable disease (SD) based on investigator assessment
Time Frame: up to 23 months
|
where best overall response is defined according to RECIST v 1.1, from first treatment administration until the earliest of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up or withdrawal of consent
|
up to 23 months
|
Overall survival (OS), defined as the time from treatment start until death from any cause
Time Frame: up to 23 months
|
up to 23 months
|
|
Change from baseline in EORTC QLQ-C30 physical functioning domain score
Time Frame: at baseline, at month 23
|
European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) The QLQ-C30 is comprised of 30 questions. It incorporates both multi-item scales and single-item measures. These include one global health status/Quality of Life (QoL) scale, five functional scales, three symptom scales and six single items to assess dyspnea, insomnia, appetite loss, constipation, diarrhoea and financial difficulties. All scales and single-item measures range in score from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning. A high score for the global health status/QoL represents a high QoL. A high score for a symptom scale/item represents a high level of symptomatology/problems. |
at baseline, at month 23
|
Change from baseline in EORTC QLQ-C30 role functioning domain score
Time Frame: at baseline, at month 23
|
at baseline, at month 23
|
|
Occurrence of treatment-emergent AEs leading to study drug discontinuation during the on-treatment period
Time Frame: up to 23 months
|
up to 23 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Lung Neoplasms
- Carcinoma
- Small Cell Lung Carcinoma
- Neuroendocrine Tumors
Other Study ID Numbers
- 1438-0005
- 2023-504247-13-00 (Registry Identifier: CTIS)
- U1111-1292-4406 (Registry Identifier: UTN, WHO registry)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".
Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Cell Lung Carcinoma
-
National Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Bladder Small Cell Neuroendocrine Carcinoma | Extrapulmonary Small Cell Neuroendocrine Carcinoma | Recurrent Lung... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterNational Institute on Aging (NIA)RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Advanced Lung Non-Small Cell Carcinoma | Advanced... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedCarcinoma, Non-Small Cell Lung | Carcinoma, Small-Cell LungUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingPlatinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Extensive Stage Lung Small Cell Carcinoma | Refractory Extensive Stage Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedExtensive Stage Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingExtensive Stage Lung Small Cell CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); Imago BioSciences, Inc., a subsidiary of Merck...SuspendedExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell CarcinomaUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Lung Small Cell CarcinomaUnited States, Canada, Korea, Republic of, Mexico
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
Clinical Trials on BI 764532, formulation 1
-
Boehringer IngelheimRecruitingPatients With Small Cell Lung Carcinoma and Other NeoplasmsUnited States, Spain, Germany, Japan
-
Boehringer IngelheimRecruitingNeuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)Netherlands
-
Boehringer IngelheimRecruitingGliomaUnited States, Switzerland
-
Boehringer IngelheimRecruitingNeuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)Germany, Belgium, Japan, France
-
Boehringer IngelheimTerminated
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimRecruiting
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted